HALO — Halozyme Therapeutics Inc COM

Ownership history in BB BIOTECH AG · 36 quarters on record

This page tracks every 13F SEC filing in which BB BIOTECH AG reported a position in Halozyme Therapeutics Inc COM (HALO). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position

6.04% (2012 Q1)

Avg. % of fund

3.38%

First filed

2010 Q2

Last filed

2019 Q1

Quarters held

36

Quarter	Action	Shares	Change	Chg %	% of Fund	Mkt Value	Price (EOQ)
2019 Q1	UNCHANGED	8,322,860	—	0%	3.37%	$134.0M	$16.10
2018 Q4	ADDED	8,322,860	+75,000	+0.9%	3.90%	$121.8M	$14.63
2018 Q3	UNCHANGED	8,247,860	—	0%	3.97%	$149.9M	$18.17
2018 Q2	REDUCED	8,247,860	-272,277	-3.2%	4.02%	$139.1M	$16.87

% of Fund (quarterly) HALO price (monthly, adj. close)

Other funds also holding HALO

As of 2025 Q4 — sorted by position size

Koa Wealth Management, LLC 4.3% SNYDER CAPITAL MANAGEMENT L P 3Y 7Y 3.01% Steamboat Capital Partners, LLC 3Y 7Y 2.66% South Street Advisors LLC 3Y 7Y 2.19% BERNZOTT CAPITAL ADVISORS 3Y 7Y 2.17% 2Xideas AG 3Y 1.98% Future Fund LLC 3Y 1.77% MIZUHO MARKETS AMERICAS LLC 3Y 1.65% Verity Asset Management, Inc. 3Y 7Y 1.53% RENAISSANCE GROUP LLC 3Y 7Y 1.3%

← Back to BB BIOTECH AG Holdings